5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human kallikrein 2 in participants with metastatic castration-resistant prostate cancer
    Journal Article

    Pandit-Taskar, N.; O'Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Ilovich, O.; Russell, M.; Nyima, T.; Divgi, C. R.; Yu, M.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • A phase 2 study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma
    Journal Article

    Msaouel, P.; Sweis, R. F.; Bupathi, M.; Heath, E.; Goodman, O. B. Jr; Hoimes, C. J.; Milowsky, M. I.; Davis, N.; Kalebasty, A. R.; Picus, J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways
    Journal Article

    Lacouture, M. E.; Goleva, E.; Shah, N.; Rotemberg, V.; Kraehenbuehl, L.; Ketosugbo, K. F.; Merghoub, T.; Maier, T.; Bang, A.; Gu, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Journal Article

    Lara, P. N.; Villanueva, L.; Ibanez, C.; Erman, M.; Lee, J. L.; Heinrich, D.; Lipatov, O. N.; Gedye, C.; Gokmen, E.; Acevedo, A.; more...
    BMC Cancer (2024)

    Fulltext@MSK | Save
  • Industry payments to physicians endorsing drugs and devices on a social media platform
    Research Letter

    Persaud, S.; Al Hadidi, S.; Anderson, T. S.; Gallagher, G.; Chimonas, S.; Korenstein, D.; Mitchell, A. P.
    JAMA - Journal of the American Medical Association (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of immune checkpoint inhibitors in unique cohorts underrepresented in clinical trials
    Journal Article

    Shah, N. J.; Della Pia, A.; Wu, T.; Williams, A.; Weber, M.; Sinclaire, B.; Paleoudis, E. G.; Alaoui, A.; Lev-Ari, S.; Adams, S.; more...
    Cancers (2024)

    Fulltext@MSK | Save
  • MicroRNA for prediction of teratoma and viable germ cell tumor after chemotherapy
    Review

    Baky, F. J.; Matulewicz, R. S.; Feldman, D. R.; Hamilton, R. J.; Bagrodia, A.
    Urologic Clinics of North America (2024)

    Fulltext@MSK | Save
  • Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma
    Editorial

    Aggen, D. H.; Rosenberg, J. E.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Characterization of responses to lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma at the final prespecified survival analysis of the phase 3 CLEAR study
    Journal Article

    Motzer, R. J.; Choueiri, T. K.; Hutson, T.; Young Rha, S.; Puente, J.; Lalani, A. K. A.; Winquist, E.; Eto, M.; Basappa, N. S.; Tannir, N. M.; more...
    European Urology (2024)

    Fulltext@MSK | Save